Siemens Healthineers AG (SEMHF)
| Market Cap | 55.42B -3.5% |
| Revenue (ttm) | 26.83B +1.1% |
| Net Income | 2.51B +3.3% |
| EPS | 2.20 +3.1% |
| Shares Out | n/a |
| PE Ratio | 22.96 |
| Forward PE | 18.78 |
| Dividend | 1.18 (2.34%) |
| Ex-Dividend Date | Feb 6, 2026 |
| Volume | 994 |
| Open | 49.95 |
| Previous Close | 49.86 |
| Day's Range | 49.18 - 50.42 |
| 52-Week Range | 37.00 - 56.39 |
| Beta | 0.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the readin... [Read more]
Financial Performance
In fiscal year 2026, Siemens Healthineers AG's revenue was 23.63 billion, an increase of 1.09% compared to the previous year's 23.38 billion. Earnings were 2.21 billion, an increase of 3.26%.
Financial numbers in EUR Financial StatementsNews
What Siemens Healthineers (SHL) Said on Its Q4 Earnings Call
Siemens Healthineers ETR: SHL expects comparable revenue growth of 4% to 5% in fiscal 2027 as it prepares for a proposed spin-off from Siemens and a separation of its Diagnostics business. The outlook...
Siemens Healthineers to Rebrand as Healthineers as Diagnostics Carve-Out Begins
The medical-technology company will drop Siemens from its name as it advances toward a spinoff from its parent group.
Siemens Healthineers AG Earnings Call Transcript: Q4 2026
FY26 comparable growth was 4%, with 8.1% Q4 growth in the synergetic core and adjusted EPS of EUR 2.42. FY27 guidance is 4%-5% revenue growth and EUR 2.20-EUR 2.40 adjusted EPS, with China, inflation and separation costs among key headwinds.
Siemens Healthineers AG Earnings release: Q4 2026
Siemens Healthineers AG released its Q4 2026 earnings on November 5, 2026, summarizing the period's financial results.
Siemens Healthineers AG Slides: Q4 2026
Siemens Healthineers AG has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on November 5, 2026.
Siemens Healthineers starts carve-out of diagnostics business
German medical technology company Siemens Healthineers (SHLG.DE), opens new tab said on Thursday it had begun carving out its diagnostics business, which it plans to rebrand as Olyrian Diagnostics a...
Siemens Healthineers Q3 Net Profit Edges Up, Adj. EBIT Drops; Issues FY27 Outlook
(RTTNews) - Siemens Healthineers AG (SMMNY.PK, SHL.DE), a German medical technology company, reported Thursday slightly higher net profit in its fourth quarter, while adjusted EBIT, a key earnings met...
Siemens Healthineers expects FY2027 revenue growth of 4%-5%
German medical technology company Siemens Healthineers forecast slower-than-expected growth in fiscal 2027 on Thursday after weakness in China continued to weigh on its diagnostics business.
EQS-AFR: Siemens Healthineers AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Siemens Healthineers AG / Preliminary announcement on the disclosure of financial statements Siemens Healthineers AG: Preliminary announcement of the pu...
Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical’s Copernicus™ program, expanding Profound’s commercial reach Profound retains direct TULSA-PRO recurr...
Siemens Healthineers AG - Depositary Receipt Consensus Price Target Decreased by 11.39% to $25.37
The average one-year price target for Siemens Healthineers AG - Depositary Receipt (OTCPK:SMMNY) (DB:SHL1) has been revised to $25.37 / share. This is a decrease of 11.39% from the prior estimate of $...
Abu Dhabi's M42 targets Africa for future growth
Abu Dhabi healthcare company M42 has signed an agreement with Siemens Healthineers, a medical technology company, to collaborate on advancing healthcare transformation in the Global South with a parti...
Siemens Healthineers price target raised to EUR 48 from EUR 45 at RBC Capital
RBC Capital analyst Natalia Webster raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 48 from EUR 45 and keeps an Outperform rating on the shares. Published first…
Siemens Healthineers price target raised to EUR 47 from EUR 46 at Citi
Citi raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 47 from EUR 46 and keeps a Buy rating on the shares.
Truvian Health Announces Strategic Alliance with Siemens Healthineers to Advance the TruVerus™ Blood Testing Platform
SAN DIEGO--(BUSINESS WIRE)--Truvian Health Announces Strategic Alliance with Siemens Healthineers to Advance the TruVerus™ Blood Testing Platform.
Siemens Healthineers AG Transcript: Pre-close call
Q4 FY26 revenue growth is expected to accelerate in imaging and precision therapy, while diagnostics continues to decline. FX provides a revenue tailwind, but inflation and other costs weigh on earnings; FY27 inflation is expected to be offset by pricing and cost measures.
Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts a...
Siemens Healthineers price target raised to EUR 46 from EUR 45 at Citi
Citi raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 46 from EUR 45 and keeps a Buy rating on the shares.
Siemens Healthineers price target raised to EUR 39 from EUR 38 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 39 from EUR 38 and keeps a Hold rating on the shares.
Siemens Healthineers AG Transcript: Status update
Q3 saw strong equipment orders and U.S. partnerships, but Diagnostics underperformed, leading to a lowered top-line outlook. Imaging revenue was delayed to Q4, which is expected to see accelerated growth. Spin-off and cost mitigation plans remain on track.
Siemens Healthineers price target raised to EUR 57.40 at JPMorgan
JPMorgan raised the firm’s price target on Siemens Healthineers (SMMNY) to EUR 57.40 from EUR 54.30 and keeps an Overweight rating on the shares.
Siemens Healthineers Q3 Earnings Call Highlights
Siemens Healthineers ETR: SHL lowered its fiscal 2026 revenue growth outlook after continued weakness in its Diagnostics business, while raising its adjusted earnings-per-share guidance to reflect tar...
Siemens Healthineers AG Earnings Call Transcript: Q3 2026
Q3 delivered strong equipment orders and solid growth in Imaging and Precision Therapy, but Diagnostics continued to decline, especially in China. Revenue guidance for FY2026 was lowered, while EPS guidance was raised due to tariff refunds. Robust order book and innovation support future growth.
Siemens Healthineers AG Earnings release: Q3 2026
Siemens Healthineers AG released its Q3 2026 earnings on July 31, 2026, summarizing the period's financial results.
Siemens Healthineers AG Slides: Q3 2026
Siemens Healthineers AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on July 31, 2026.